Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 15/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8693976 | 0.90 | KDM4E (0.58) | HRH4KDM4ERXFP1 | |
| SCHEMBL81467 | 0.79 | HRH4 (0.57) | HRH4HRH3 | |
| SCHEMBL13035375 | 0.79 | KDM4E (0.52) | KDM4ERXFP1 | |
| SCHEMBL13118511 | 0.78 | HRH4 (0.57) | HRH4HRH3 | |
| SCHEMBL28850160 | 0.77 | HRH4 (0.59) | HRH4HRH3 | |
| SCHEMBL4287133 | 0.76 | HRH4 (0.64) | HRH4HRH3 | |
| SCHEMBL24928451 | 0.76 | KDM4E (0.52) | KDM4ERXFP1 | |
| SCHEMBL1267664 | 0.76 | KDM4E (0.49) | KDM4ERXFP1 | |
| SCHEMBL30718898 | 0.76 | KDM4E (0.52) | KDM4ERXFP1 | |
| SCHEMBL27140276 | 0.76 | KDM4E (0.52) | KDM4ERXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | HRH4 3347/4885KDM4E 2865/4885HRH3 3986/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | HRH4 3520/4885KDM4E 3393/4885HRH3 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.